Banco Bilbao Vizcaya Argentaria S.A. Increases Bristol Myers Squibb Stake

The Spanish bank now owns over $29 million in shares of the biopharmaceutical company.

Mar. 15, 2026 at 8:22am

Got story updates? Submit your updates here. ›

Banco Bilbao Vizcaya Argentaria S.A., a major Spanish bank, increased its holdings in Bristol Myers Squibb Company by 2.9% during the third quarter of 2025. The bank now owns 656,339 shares of the biopharmaceutical company's stock, valued at $29.6 million.

Why it matters

This investment by a large European financial institution highlights the continued confidence in Bristol Myers Squibb's business and growth prospects among institutional investors. As a leading global biopharmaceutical company, Bristol Myers Squibb's performance is closely watched by the investment community.

The details

According to a recent SEC filing, Banco Bilbao Vizcaya Argentaria S.A. added 18,244 shares of Bristol Myers Squibb to its portfolio during the third quarter of 2025. This increased the bank's total stake in the company to 656,339 shares, worth approximately $29.6 million. The filing indicates the bank's holdings now represent 2.9% of Bristol Myers Squibb's outstanding shares.

  • Banco Bilbao Vizcaya Argentaria S.A. filed the SEC report detailing its increased Bristol Myers Squibb holdings on March 15, 2026.
  • The bank added the additional 18,244 shares to its portfolio during the third quarter of 2025.

The players

Banco Bilbao Vizcaya Argentaria S.A.

A major Spanish banking group and one of the largest financial institutions in Europe.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Banco Bilbao Vizcaya Argentaria's increased investment in Bristol Myers Squibb reflects the Spanish bank's confidence in the biopharmaceutical company's long-term growth potential. As a major institutional investor, the bank's stake in Bristol Myers Squibb is seen as a vote of confidence in the company's strategic direction and pipeline of innovative medicines.